Viz.ai Wins 2025 Edison Award™ for Machine Learning Innovation for the Third Consecutive Year

Rhea-AI Summary

Viz.ai has secured its third consecutive Edison Award™ for innovation in cardiovascular health diagnostics, specifically for its Viz HCM module. The AI-powered software, developed in partnership with Bristol Myers Squibb (NYSE:BMY), received FDA De Novo approval in August 2023 for detecting hypertrophic cardiomyopathy (HCM).

The Viz HCM module analyzes 12-lead ECGs across healthcare systems to identify potential HCM cases and alert cardiology teams. Recent data from Cleveland Clinic demonstrated the software's effectiveness, identifying 574 HCM patients during a 9-month period. This is particularly significant as HCM, despite being the most commonly inherited cardiac disease, has only a 15% diagnosis rate.

The Edison Awards, named after Thomas Alva Edison, recognize excellence in innovation and business success. The winners were announced at the Edison Awards Gala on April 3, 2025, in Fort Myers, FL.

Honored for excellence and innovation in cardiovascular health diagnostics for Viz HCM module

SAN FRANCISCO--(BUSINESS WIRE)-- Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced that it has been named an Award Winner in the 2025 Edison Awards, for the third year in a row. Viz HCM, the company’s AI software solution designed to detect and triage patients with signs of hypertrophic cardiomyopathy (HCM), was recognized in the Health Medical & Biotech category and Cardiovascular Health Diagnostics and Monitoring subcategory. The Edison Awards, named after the American inventor Thomas Alva Edison, honor excellence in new product and service development, marketing, design and innovation. The awards are widely recognized as one of the premier accolades that companies can receive in the name of innovation and business success.

“We are honored to win our third, prestigious Edison Award, reaffirming our mission-critical work to transform AI-driven healthcare,” said Dr. Chris Mansi, CEO and co-founder of Viz.ai. “HCM is an underdiagnosed condition that is the most commonly inherited cardiac disease, yet, unfortunately only 15% of these patients are diagnosed. The recognition of Viz HCM, which accelerates the patient identification and journey for this serious disease, validates our efforts to help clinicians to deliver faster and better care.”

Viz HCM uses artificial intelligence to analyze all 12-lead electrocardiograms (ECGs) from across a health system to identify suspected HCM cases, notify cardiology care teams and increase the likelihood that patients get the right follow-up and diagnosis. The Viz HCM module, developed as part of a multi-year funding agreement between Viz.ai and Bristol Myers Squibb (NYSE:BMY), was granted De Novo approval by the FDA in August 2023, creating a new regulatory category for cardiovascular machine learning-based notification software. Recent data, presented at the American College of Cardiology meeting, demonstrated that Viz HCM successfully helped identify 574 HCM patients in a single major academic hospital (Cleveland Clinic) in a 9 month period, highlighting Viz HCM’s ability for more effective disease detection.¹

All nominations are reviewed by the Edison Awards’ Steering Committee and an executive judging body. The panel is composed of more than 2,000 senior business executives and academics from the fields of product development, design, engineering, science, marketing and education, as well as past winners.

Winners were announced at the Edison Awards Gala on April 3, 2025 in Fort Myers, FL.

For more information on Viz HCM, please visit https://www.viz.ai/hypertrophic-cardiomyopathy.

¹ Real-World Artificial Intelligence–Based Electrocardiographic Analysis to Diagnose Hypertrophic Cardiomyopathy. JACC: Clinical Electrophysiology. https://www.jacc.org/doi/10.1016/j.jacep.2025.02.024

About Viz.ai

Viz.ai is the pioneer in the use of AI algorithms and machine learning to increase the speed of diagnosis and care across 1,700+ hospitals and health systems in the U.S. and Europe. The AI-powered Viz.ai One® is an intelligent care coordination solution that identifies more patients with a suspected disease, informs critical decisions at the point of care, and optimizes care pathways and helps improve outcomes. Backed by real-world clinical evidence, Viz.ai One delivers significant value to patients, providers, and pharmaceutical and medical device companies. For more information visit Viz.ai.

About The Edison Awards

Established in 1987, the Edison Awards are dedicated to recognizing, honoring and fostering innovations and innovators. Named after Thomas Alva Edison (1847-1931), the annual competition honors excellence in new product and service development, marketing, human-centered design and innovation. Past award recipients include Jony Ive, Martha Stewart, Carmichael Roberts and companies leading in innovation including; Nest, now part of Google, AMD, Intel, Naqi, 3M and Cargill. In 2021, the Edison Awards introduced the inaugural Lewis Latimer Fellowship program designed to celebrate, connect and bring together a community of innovative Black thought leaders. For more information, visit www.edisonawards.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250404957152/en/

Media Contact

Carolyn Jones

carolyn.jones@viz.ai

Daniel Yunger

daniel.yunger@kekstcnc.com

Source: Viz.ai

FAQ

What is the success rate of Viz.ai's HCM module in detecting hypertrophic cardiomyopathy cases?

In a recent study at Cleveland Clinic, Viz HCM successfully identified 574 HCM patients over a 9-month period, demonstrating significant effectiveness in disease detection.

When did Viz HCM receive FDA approval and what was Bristol Myers Squibb's (BMY) involvement?

Viz HCM received FDA De Novo approval in August 2023, developed through a multi-year funding agreement with Bristol Myers Squibb (BMY), creating a new regulatory category for cardiovascular ML-based notification software.

How does Viz.ai's HCM technology work in healthcare systems?

The technology analyzes all 12-lead electrocardiograms (ECGs) across a health system to identify suspected HCM cases and automatically notify cardiology care teams for appropriate follow-up and diagnosis.

What is the current diagnosis rate for HCM, and why is Viz.ai's technology important?

Only 15% of HCM patients are currently diagnosed, despite it being the most commonly inherited cardiac disease, making Viz.ai's AI-powered detection technology important for improving diagnosis rates.

How many consecutive Edison Awards has Viz.ai won and in which category was Viz HCM recognized?

Viz.ai has won the Edison Award for three consecutive years, with Viz HCM being recognized in the Health Medical & Biotech category and Cardiovascular Health Diagnostics and Monitoring subcategory.